DOI QR코드

DOI QR Code

Prevention and Adjuvant Therapy of Recurrent Respiratory Papillomatosis

재발성 호흡기 유두종증의 예방과 보조 요법

  • Lee, Dong Kun (Department of Otolaryngology-Head and Neck Surgery, Dong-A University College of Medicine)
  • 이동근 (동아대학교 의과대학 이비인후-두경부외과학교실)
  • Received : 2020.06.01
  • Accepted : 2020.06.12
  • Published : 2020.06.30

Abstract

Recurrent respiratory papillomatosis (RRP) is characterized by repeated recurrence in the respiratory system, such as the pharynx, larynx, and trachea, caused by the human papilloma virus. The main treatment is surgical removal of the papilloma. However repeated recurrence of RRP in multiple areas is burdened for the surgeon. In addition to the surgery, various adjuvant therapies have been studied to reduce the recurrence. Literature review was conducted with a focus on the adjuvant treatments for RRP.

Keywords

References

  1. Marsico M, Mehta V, Chastek B, Liaw KL, Derkay C. Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States. Sex Transm Dis 2014;41(5):300-5. https://doi.org/10.1097/OLQ.0000000000000115
  2. Venkatesan NN, Pine HS, Underbrink MP. Recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2012;45(3):671-94, viii-ix. https://doi.org/10.1016/j.otc.2012.03.006
  3. Taliercio S, Cespedes M, Born H, Ruiz R, Roof S, Amin MR, et al. Adult-onset recurrent respiratory papillomatosis: a review of disease pathogenesis and implications for patient counseling. JAMA Otolaryngol Head Neck Surg 2015;141(1):78-83. https://doi.org/10.1001/jamaoto.2014.2826
  4. Corbitt G, Zarod AP, Arrand JR, Longson M, Farrington WT. Human papillomavirus (HPV) genotypes associated with laryngeal papilloma. J Clin Pathol 1988;41(3):284-8. https://doi.org/10.1136/jcp.41.3.284
  5. Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol 2001;4(1):68-72. https://doi.org/10.1007/s100240010105
  6. Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 2004;130(9):1039-42. https://doi.org/10.1001/archotol.130.9.1039
  7. Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a stateof-the-art review. Respir Med 2017;126:116-21. https://doi.org/10.1016/j.rmed.2017.03.030
  8. Limsukon A, Susanto I, Soo Hoo GW, Dubinett SM, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest 2009;136(3):924-6. https://doi.org/10.1378/chest.08-2639
  9. Holland BW, Koufman JA, Postma GN, McGuirt WF Jr. Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas. Laryngoscope 2002;112(11):1926-9. https://doi.org/10.1097/00005537-200211000-00003
  10. Borkowski G, Sommer P, Stark T, Sudhoff H, Luckhaupt H. Recurrent respiratory papillomatosis associated with gastroesophageal reflux disease in children. Eur Arch Otorhinolaryngol 1999;256(7):370-2. https://doi.org/10.1007/s004050050166
  11. Harcourt JP, Worley G, Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 1999;51(2):109-13. https://doi.org/10.1016/S0165-5876(99)00279-7
  12. McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol 2005;69(5):597-605. https://doi.org/10.1016/j.ijporl.2004.11.021
  13. Pashley NR. Can mumps vaccine induce remission in recurrent respiratory papilloma?. Arch Otolaryngol Head Neck Surg 2002;128(7):783-6. https://doi.org/10.1001/archotol.128.7.783
  14. Lei J, Yu W, Yuexin L, Qi C, Xiumin S, Tianyu Z. Topical measlesmumps-rubella vaccine in the treatment of recurrent respiratory papillomatosis: results of a preliminary randomized, controlled trial. Ear Nose Throat J 2012;91(4):174-5. https://doi.org/10.1177/014556131209100411
  15. Wang Y, Dai PD, Zhang TY. Experimental research on the therapeutic effect of MMR vaccine to juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2019;276(3):801-3. https://doi.org/10.1007/s00405-019-05351-6
  16. Meacham RK, Thompson JW. Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. Ear Nose Throat J 2017;96(2):69-74. https://doi.org/10.1177/014556131709600209
  17. Leventhal BG, Kashima HK, Weck PW, Mounts P, Whisnant JK, Clark KL, et al. Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis. Arch Otolaryngol Head Neck Surg 1988;114(10):1163-9. https://doi.org/10.1001/archotol.1988.01860220097032
  18. Lee JH, Smith RJ. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 2005;13(6):354-9. https://doi.org/10.1097/01.moo.0000186205.91332.46
  19. Maunsell R, Bellomo-Brandao MA. Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report. Sao Paulo Med J 2018;136(4):376-81. https://doi.org/10.1590/1516-3180.2017.0031240317
  20. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med 1988;319(7):401-7. https://doi.org/10.1056/NEJM198808183190704
  21. Suter-Montano T, Montano E, Martinez C, Plascencia T, Sepulveda MT, Rodriguez M. Adult recurrent respirator papillomatosis: a new therapeutic approach with pegylated interferon alpha 2a (Peg-$IFN{\alpha}$-2a) and GM-CSF. Otolaryngol Head Neck Surg 2013;148(2):253-60. https://doi.org/10.1177/0194599812466226
  22. Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol 2005;114(6):463-71. https://doi.org/10.1177/000348940511400608
  23. Szeps M, Dahlgren L, Aaltonen LM, Ohd J, Kanter-Lewenshon L, Dahlstrand H, et al. Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment. J Gen Virol 2005;86(Pt 6):1695-702. https://doi.org/10.1099/vir.0.80849-0
  24. Foldvari M, Kumar P. Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection. Ther Deliv 2012;3(8):1005-17. https://doi.org/10.4155/tde.12.78
  25. Dion GR, Teng S, Boyd LR, Northam A, Mason-Apps C, Vieira D, et al. Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review. JAMA Otolaryngol Head Neck Surg 2017;143(6):614-22. https://doi.org/10.1001/jamaoto.2016.4736
  26. Meszner Z, Jankovics I, Nagy A, Gerlinger I, Katona G. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. Int J Pediatr Otorhinolaryngol 2015;79(2):262-6. https://doi.org/10.1016/j.ijporl.2014.11.022
  27. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998;108(7):962-7. https://doi.org/10.1097/00005537-199807000-00002
  28. Shikowitz MJ, Abramson AL, Steinberg BM, DeVoti J, Bonagura VR, Mullooly V, et al. Clinical trial of photodynamic therapy with mesotetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2005;131(2):99-105. https://doi.org/10.1001/archotol.131.2.99
  29. Bell R, Hong WK, Itri LM, McDonald G, Strong MS. The use of cisretinoic acid in recurrent respiratory papillomatosis of the larynx: a randomized pilot study. Am J Otolaryngol 1988;9(4):161-4. https://doi.org/10.1016/S0196-0709(88)80023-1
  30. Lippman SM, Donovan DT, Frankenthaler RA, Weber RS, Earley CL, Hong WK, et al. 13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis. J Natl Cancer Inst 1994;86(11):859-61. https://doi.org/10.1093/jnci/86.11.859
  31. Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 2013;139(5):496-501. https://doi.org/10.1001/jamaoto.2013.1810
  32. Clamp PJ, Saunders MW. Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2013;77(3):323-8. https://doi.org/10.1016/j.ijporl.2012.12.027
  33. Derkay CS, Volsky PG, Rosen CA, Pransky SM, McMurray JS, Chadha NK, et al. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2013;123(3):705-12. https://doi.org/10.1002/lary.23673
  34. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999;125(10):1143-8. https://doi.org/10.1001/archotol.125.10.1143
  35. Naiman AN, Ceruse P, Coulombeau B, Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 2003;113(12):2174-81. https://doi.org/10.1097/00005537-200312000-00024
  36. Chadha NK, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev 2010;(1):CD005053.